Track ZNTL and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Main
Market Cap$328.84M
Enterprise Value$120.95M
Revenue (TTM)-
Net Income (TTM)-$124.13M
Free Cash Flow (TTM)-$125.60M
Financial Health
Cash$211.76M
Net Debt-$207.88M
Debt Ratio0.02
Debt to Equity0.02
Interest Coverage-
Valuation (TTM)
Price to Sales-
Price to Earnings-2.65
EV to EBITDA-0.89
Price to Book1.8
Price to Free Cash Flow-2.62
Margins (TTM)
Gross Profit Margin-
EBITDA Margin-
Operating Income Margin-
Net Income Margin-
Free Cash Flow Margin-
Returns (5Y Avg)
Return on Invested Capital-53.86%
Return on Assets-47.04%
Return on Equity-55.52%
Return on Total Capital-53.86%
Return on Capital Employed-53.14%
Dividend Summary
Dividend Yield-
Annual Dividend-
Payout Ratio-
Ex Dividend Date-
5-Year Dividend CAGR-
CAGR (5Y)
Revenue0.00%
Diluted EPS8.11%
Total Debt33.83%
Capital Expenditures-93.33%
Free Cash Flow-7.20%
CAGR (3Y)
Revenue0.00%
Diluted EPS41.54%
Total Debt21.45%
Capital Expenditures-99.27%
Free Cash Flow25.46%
CAGR (1Y)
Revenue-100.00%
Diluted EPS41.56%
Total Debt26.07%
Capital Expenditures-100.00%
Free Cash Flow1000.00%
$4.78+$0.01|+0.21%
52W High$6.95
52W Low$1.21
50D SMA$4.08
200D SMA$2.75
Volume675.91K
Zentalis Pharmaceuticals Llc
10275 Science Center Dr., San Diego, CA, United States, 92121
IPO
2020
Employees
106
Industry
Biotechnology
Sector
Healthcare
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is based in San Diego, California.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q1 20267-7
0
Q4 202510
1
Q2 20250+1
1
3-quarter cumulative
8 sells2 buys
Analyst Ratings
7 analysts covering
Hold86%recommend hold
Buy
1
Hold
6
Sell
0